Connect Biopharma Holdings Limited

NASDAQ:CNTB

Biotechnology

Healthcare
$0.80 -4.09%

-$0.09 today

Market cap
$50.52M
Beta
-0.21
P/E (TTM)
-4.0
EPS (TTM)
-$0.50
52W Low $0.91High $3.82

Volume 2.50M

Average 0.30M

CNTB EBITDA Margin

EBITDA as a percentage of revenue.

Connect Biopharma Holdings LimitedNASDAQ: CNTB

EBITDA Margin · Q4 FY2025 · quarter ended Dec 2025

EBITDA Margin not reported for Q4 FY2025

What to watch

Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -721.5% for the fiscal year ending Dec 2026, up from -85279.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
—— QoQ
Last fiscal yearDec 2025
-85279.7%-85223.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year-85223.0 pp+84558.2 pp+169781.2 pp
3 years—+84673.9 pp—
5 years+85240.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-85279.7%
Year-over-year change
-85223.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CNTB compares with its peers on the latest reported figures

  • CNTB's FY2025 EBITDA Margin of -85279.7% is the 5th highest of the 6 companies compared; the peer median is -4623.1%.
  • Its year-over-year change of -85223.0 pp is the 5th highest of 6, against a peer median of -3172.4 pp.
CNTB Competitors Peer median
EBITDA Margin for CNTB and competitors
Company Period LTM level YoY 3-year change
STROSutro Biopharma, Inc.LTM Mar 2026-106.5% +169.1 pp+12.9 pp
OVIDOvid Therapeutics Inc.LTM Mar 2026-337.0% +4411.9 pp+3368.5 pp
STTKShattuck Labs, Inc.LTM Mar 2026-4623.1% -3172.4 pp+10652.3 pp
IMAImageneBio IncFY2025-5583.3% -4582.4 pp-5147.8 pp
CNTBConnect Biopharma Holdings LimitedFY2025-85279.7% -85223.0 pp—
IFRXInflaRx N.V.LTM Mar 2026-144435.8% -111246.8 pp—
ARTVArtiva Biotherapeutics, Inc.FY2025— ——
KLRSKalaris Therapeutics IncFY2025— ——
CNTXContext Therapeutics Inc.FY2025— ——
Peer median (excluding CNTB) -4623.1%-3172.4 pp+1690.7 pp

Competitors are the stored peer set for CNTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00026.03M64K
Cost of Revenue00000
Gross Profit00026.03M64K
Gross Margin———100.0%100.0%
Research & Development80.5M96.63M53M29.26M37.8M
Selling, General & Admin19.01M20.81M16.05M19.23M20.34M
Operating Expenses98.11M119.32M69.06M48.49M58.14M
Depreciation & Amortization634K1.03M720K660K704K
EBITDA(201.36M)(116.74M)(61.27M)(14.75M)(54.58M)
EBITDA Margin———-56.6%-85279.7%
Operating Income(98.11M)(119.32M)(69.06M)(22.45M)(58.07M)
Operating Margin———-86.2%-90740.6%
Interest Income97.67K1.56M5.2K4.45M2.27M
Interest Expense6.91K21.03K000
Other Income / Expenses(103.89M)1.52M7.07M7.05M2.79M
Income Before Tax(202M)(117.79M)(61.99M)(15.41M)(55.28M)
Pre-Tax Margin———-59.2%-86379.7%
Income Tax Expense266K298K120K223K197K
Net Income(202.27M)(118.09M)(62.11M)(15.63M)(55.48M)
Net Margin———-60.0%-86687.5%
EPS (Basic)(25.00)(14.50)(1.08)(0.28)(1.00)
EPS (Diluted)(25.00)(14.50)(1.08)(0.28)(1.00)
Weighted Avg Shares52.27M55.04M55.07M55.21M55.66M
Weighted Avg Shares (Diluted)52.27M55.04M55.07M55.21M55.66M

Connect Biopharma Holdings Limited

NASDAQ:CNTB

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.